Light Therapy: Red Light, Near-Infrared, Blue Light, and Photobiomodulation

Visible light occupies the 380–700 nm band of the electromagnetic spectrum, flanked by ultraviolet (10–380 nm) below and near-infrared (700–2500 nm) above. Sunlight delivers all of these wavelengths at ground level, though atmospheric absorption by ozone removes most UV-C (<280 nm) and the solar spectrum shifts dramatically with the angle of incidence — sunrise and sunset light is enriched in red and NIR because the longer atmospheric path scatters shorter wavelengths away. Human tissue is not a uniform medium; different chromophores absorb specific wavelengths and set strict limits on how deep light penetrates.

The "optical window" or "therapeutic window" refers to the 600–1100 nm band where tissue absorption is at its minimum and photons can travel deepest. Below 600 nm, haemoglobin and its oxygenated forms absorb strongly — red light below about 590 nm is almost entirely absorbed within the first millimetre of skin. Above 1100 nm, water absorbs heavily, producing heat rather than bioactive photons. Within the 600–1100 nm window, penetration depths depend on tissue type: skin and subcutaneous fat allow 5–10 mm for 660 nm and 20–30 mm for 810 nm; bone cortex, being highly scattering, reduces penetration further; the calvarium attenuates 810 nm by roughly 80% before it reaches cortical brain tissue, yet measurable irradiance does reach superficial cortex.

UV radiation deserves separate treatment because its biological effects are fundamentally different from photobiomodulation. UV-B (280–315 nm) photons carry enough energy to convert 7-dehydrocholesterol in skin to previtamin D3, and UVA (315–400 nm) drives nitric oxide (NO) release from cutaneous stores — a vasodilatory and blood-pressure-lowering effect that requires outdoor exposure (window glass blocks virtually all UV-B). Neither photobiomodulation panels nor standard bright-light therapy boxes emit meaningful UV; they operate via entirely different mechanisms from those covered in the PBM literature. Understanding these spectral distinctions is essential before interpreting claims about any specific device or protocol.

Photobiomodulation (PBM), previously termed low-level laser therapy (LLLT) or low-level light therapy (LLLT), refers to the use of red and near-infrared photons to produce non-thermal biological effects. The primary chromophore mediating these effects at the cellular level is cytochrome c oxidase (CCO, Complex IV) of the mitochondrial electron transport chain. CCO contains two copper centres (Cu_A and Cu_B) and two haem iron centres (haem a and haem a3) whose absorption spectra include peaks at approximately 620–680 nm and 760–830 nm — closely matching the therapeutic wavelength windows documented in PBM research. Pioneering work by Tiina Karu in the 1980s–2000s established CCO as the photoabsorber responsible for the downstream mitochondrial effects, and this model has since been elaborated by Hamblin, de Freitas, Bhatt, and others.

When CCO absorbs red/NIR photons, its activity increases: the enzyme pumps protons more efficiently across the inner mitochondrial membrane, elevating the proton motive force and accelerating ATP synthase (Complex V). Net effect: higher intracellular ATP at a given substrate availability. Simultaneously, PBM modulates reactive oxygen species (ROS) in a dose-dependent, hormetic fashion. At low doses, a brief, controlled rise in mitochondrial ROS activates redox-sensitive transcription factors — primarily NF-κB, AP-1, and Nrf2 — which upregulate antioxidant enzymes, anti-apoptotic proteins, and pro-survival genes. This is the same hormesis principle seen with exercise-derived ROS: the signal is beneficial; only chronic excess is damaging. Alongside ROS, PBM causes photodissociation of nitric oxide from CCO — NO reversibly inhibits CCO by competing with oxygen at the Cu_B/haem a3 site, and its removal restores enzyme activity while releasing free NO, which acts as a local vasodilator and secondary signalling molecule.

Downstream from these primary mitochondrial events, PBM triggers a cascade of secondary effects over hours and days: increased VEGF (angiogenesis), upregulated TGF-β and collagen synthesis (wound healing), reduced TNF-α and IL-6 (anti-inflammatory), enhanced BDNF and NGF expression in neurons (neuroprotection), and proliferation of fibroblasts, keratinocytes, and satellite muscle cells. These effects collectively explain why the clinical evidence spans such apparently disparate conditions — the mechanism is essentially cellular bioenergetics and redox signalling, and the affected tissues are wherever photons reach in sufficient quantity. The dose–response (J/cm²) follows the Arndt–Schulz law: no effect at very low doses, stimulation at intermediate doses, inhibition at excessive doses — which means both underdosing and overdosing result in lost efficacy.

At wavelengths of 630–680 nm, red light penetrates 5–10 mm into skin — sufficient to reach the dermis, follicular bulge, and superficial wound beds, but not deep muscle or bone. The strongest clinical evidence in this range is for cutaneous wound healing. A 2014 systematic review by Chaves et al. (covering 26 RCTs) found that low-level laser therapy at 630–670 nm significantly accelerated wound closure versus controls, with effect sizes for healing speed ranging from 30–50% improvement in chronic diabetic ulcers. A 2021 Cochrane review on LLLT for pressure ulcers identified low-to-moderate quality evidence of benefit, noting that heterogeneity in dose (2–32 J/cm²), wavelength (630–900 nm), and wound type made pooling difficult.

Androgenetic alopecia (male and female pattern hair loss) has the most rigorous RCT evidence in the scalp application of red light. A 2014 double-blind RCT by Lanzafame et al. (n=44) using an 655 nm helmet device found a 35% increase in hair count versus sham at 16 weeks (p<0.0001). A subsequent 2013 meta-analysis by Avci et al. in Lasers in Surgery and Medicine confirmed statistically significant increases in hair density across six RCTs using 630–670 nm devices. Proposed mechanisms include increased blood flow to follicles, stimulation of the anagen growth phase, and reduced follicular apoptosis via Bcl-2 upregulation. The FDA has cleared several LLLT hair devices under the 510(k) pathway, placing this among the most robustly supported consumer applications.

Skin rejuvenation and collagen induction represent a growing body of evidence. A 2014 RCT by Wunsch and Matuschka (n=136) used 633 nm and 830 nm panels in combination, finding significant improvements in skin roughness (measured profilometrically), procollagen I expression (+31% at biopsy), and dermal density on ultrasound after 30 bi-weekly 15-minute sessions. A 2007 open-label study by Weiss et al. (n=900) treating facial photoageing with 590 nm + 870 nm found 90% of subjects reported improvement at 12 weeks. These findings are consistent with the known effects of red light on fibroblast activation and TGF-β1/collagen type I gene expression in vitro. Limitations include small sample sizes, lack of long-term follow-up, and commercial sponsorship in several trials — all factors that warrant caution when extrapolating from device marketing materials.

Near-infrared wavelengths (800–1100 nm) penetrate substantially deeper than red light due to reduced haemoglobin absorption in this range. Clinically relevant depths for 810–850 nm reach 20–30 mm through skin and subcutaneous fat, which is sufficient to reach intra-articular structures (knee joint, wrist, temporomandibular joint), musculotendinous junctions, vertebral facet joints, and — at sufficiently high doses — superficial brain parenchyma through the calvarium. This broader tissue reach underlies the breadth of NIR clinical applications. The mechanism remains CCO stimulation, with secondary modulation of inflammatory cytokines, local NO, and prostaglandin E2.

Musculoskeletal pain is the most studied NIR application. A 2009 Cochrane review by Bjordal et al. on LLLT for osteoarthritis identified 9 RCTs showing significant pain reduction versus sham (weighted mean difference −24 mm on a 100 mm VAS) with a mean dose of approximately 7.5 J/cm² at 820–904 nm. A 2017 meta-analysis by Stausholm et al. (22 RCTs, n=1,062) reaffirmed these findings, reporting a 26–36% reduction in pain scores versus sham controls (standardised mean difference −0.65, 95% CI −0.88 to −0.43) for knee osteoarthritis treated with 780–860 nm devices at doses of 6–12 J/cm². For chronic low back pain, a 2015 RCT by Djavid et al. (n=61) comparing 830 nm LLLT + exercise versus exercise alone found significantly greater pain reduction and disability improvement at 8 weeks in the combined group. Effect sizes are generally moderate but clinically meaningful for a non-pharmacological intervention.

Transcranial photobiomodulation (tPBM) for neurological conditions is an emerging and rapidly expanding field. The principle is delivery of 808–1064 nm light transdermally through the skull to cortical tissue. A 2017 sham-controlled pilot RCT by Naeser et al. (n=11, chronic TBI) found significant improvements in executive function, verbal memory, and PTSD symptoms after 18 sessions of 633 nm + 870 nm transcranial delivery; effect sizes were large (d=0.8–1.3) but the sample was small. A 2021 review by Hamblin in Photochemistry and Photobiology identified over 30 animal studies showing neuroprotective effects of NIR after TBI, stroke, and neurodegeneration, with eight human trials suggesting feasibility and positive signals. The greatest challenge is delivering sufficient irradiance through the skull (which attenuates 808 nm by ~60–80%), which has pushed research toward 1064 nm (less scatter) and continuous-wave versus pulsed delivery comparisons. This remains a pre-mature application for general consumer use, but the mechanistic and early clinical signals are sufficiently strong to warrant controlled trials.

Blue light (400–500 nm, peak circadian sensitivity ~480 nm) is the most potent suppressor of melatonin synthesis and the strongest driver of circadian phase delay. The mechanism runs through intrinsically photosensitive retinal ganglion cells (ipRGCs) expressing the photopigment melanopsin (OPN4), which has a peak absorption at ~480 nm. Unlike rods and cones, ipRGCs are slow-adapting and sum light over extended exposures — meaning that sustained evening exposure to blue-enriched light (blue-white LEDs, smartphones, tablets) generates prolonged non-image-forming signals to the suprachiasmatic nucleus (SCN) that suppress melatonin from the pineal gland and delay circadian phase. A 2014 study by Chang et al. in PNAS (n=12) found that evening reading on a blue-light-emitting e-reader versus a print book suppressed melatonin by 55%, delayed melatonin onset by 1.5 hours, and reduced REM sleep the following night. Morning alertness and reaction time were also impaired.

Retinal phototoxicity from blue light is a distinct concern from its circadian effects. Blue and violet photons (400–460 nm) generate reactive oxygen species in retinal pigment epithelium (RPE) cells via photosensitisation of lipofuscin A2E, a metabolic byproduct that accumulates with age. This "blue-light hazard" was established in the 1990s in cell models, but whether consumer-level screen irradiance is sufficient to cause meaningful retinal damage in normal use remains debated. The American Academy of Ophthalmology has stated that ordinary screen use does not damage retinas and that no clear evidence supports anti-blue-light lenses for this purpose. However, chronic exposure to high-intensity blue-enriched lighting (poorly designed LED streetlights, industrial settings) over decades is a legitimate concern for cumulative RPE stress, and several population studies suggest associations between photoreceptor loss and greater ambient light exposure at higher blue fractions. The circadian disruption risk is mechanistically established and quantifiable; the retinal phototoxicity risk from screens is probable but unquantified in population terms.

Blue-light-blocking glasses (BLBs) with orange or amber lenses (filtering <530 nm) reduce melatonin suppression by 40–58% in controlled exposure studies. A 2021 crossover RCT by Hester et al. (n=30) found that amber BLBs worn two hours before bed improved sleep onset latency by ~9 minutes and increased total sleep time by ~24 minutes versus clear lenses on the same screen-exposure protocol. A 2017 randomised trial by Burkhart and Phelps (n=20, insomnia patients) found amber BLBs for three hours before bed reduced Pittsburgh Sleep Quality Index scores significantly versus clear lenses at 2 weeks. However, the most pragmatic strategy remains reducing total light intensity after sunset — dimming screens to ≤50 nits and switching to warm-tone (>2700 K) bulbs after dark is as effective as spectral filtering and carries no cost. BLBs add incremental benefit for people who cannot reduce brightness, or who work in bright offices in the evening.

Bright light therapy (BLT) for seasonal affective disorder (SAD) is one of the most evidence-dense non-pharmacological interventions in psychiatry. Standard protocol: 10,000 lux broad-spectrum white light (UV-filtered), 20–30 cm from the eyes, every morning for 30 minutes, starting within the first hour of awakening. A 2005 meta-analysis by Golden et al. in the American Journal of Psychiatry (23 RCTs, n=694) found effect sizes for BLT of d=0.84 for SAD and d=0.53 for non-seasonal depression — comparable to or exceeding antidepressant monotherapy in those populations, with a number needed to treat (NNT) of approximately 2.5 for SAD remission at six weeks. Onset of action is faster than antidepressants: many patients report improvement within 3–7 days.

The mechanism of BLT in mood disorders is not fully resolved but involves multiple pathways. Most prominently, morning bright light shifts circadian phase earlier (phase advance), which is hypothesised to correct the phase delay or internal circadian desynchrony that characterises winter depression. Serotonin availability is also relevant: a 2002 PET study by Bhagwagar et al. found reduced serotonin transporter binding in SAD patients, and BLT upregulates serotonin synthesis in the dorsal raphe, an effect measurable within hours. Separately, light exposure activates pupillary reflexes and ipRGC projections to the lateral habenula and other limbic structures, suppressing negative affect signals independent of the melatonin pathway. This multi-pathway model explains why BLT augmentation benefits non-seasonal major depression too: a 2016 RCT by Lam et al. in JAMA Psychiatry (n=122) found that BLT + placebo was superior to fluoxetine + placebo and to BLT + fluoxetine was superior to both alone, with remission rates of 43.8% for combination therapy versus 19.4% for fluoxetine alone at 8 weeks.

Bipolar disorder requires specific caution with BLT. Bright light, particularly without concurrent mood stabilisation, can trigger hypomanic or manic episodes in bipolar I and II patients — a risk documented in case series and mechanistically plausible given light's activating effects on dopamine and the circadian axis. A 2017 RCT by Sit et al. (n=46, bipolar depression) found that midday BLT at 7,000 lux was effective and safer than morning delivery (which triggered more hypomania), supporting a shift to midday administration in bipolar populations when light therapy is used. Clinical guidelines (CANMAT, British Association for Psychopharmacology) recommend BLT as a first-line treatment for SAD and an augmentation strategy for non-seasonal depression, always combined with standard care. Self-prescribing BLT without psychiatric evaluation is not advised for anyone with a known or suspected bipolar spectrum diagnosis.

Morning outdoor sunlight is the original and most potent circadian zeitgeber available without devices. The critical variable is not just total photon exposure but spectral composition, irradiance, and the retinal angle of light entry. In the first 1–2 hours after sunrise, the sun is below ~30° elevation and the light is enriched in red and NIR (long atmospheric path scattering away blue) with progressively increasing blue as the sun rises. The ipRGC system, however, does not require blue-enriched light exclusively — at sufficient intensity (>1000 lux), the full visible spectrum activates melanopsin sufficiently to signal the SCN. Outdoor illuminance on a clear morning exceeds 10,000–100,000 lux, dwarfing the 50–500 lux typical of indoor environments. Even 10–15 minutes of direct outdoor light (no sunglasses, facing the sky but not looking directly at the sun) within one hour of waking is sufficient to generate a strong zeitgeber signal in most latitudes.

Vitamin D synthesis is a distinct benefit of morning sunlight but operates on different physics. UVB photons (280–315 nm) convert 7-dehydrocholesterol (7-DHC) in skin to pre-vitamin D3, which then thermally isomerises to vitamin D3 over hours. UVB irradiance depends on solar elevation — at angles below ~15°–20° (early morning and evening, winter latitudes above 35°N or 35°S), the UV index is so low (<1–2) that negligible vitamin D is synthesised regardless of duration. Peak UVB exposure occurs when shadows are shorter than your height (solar elevation >45°), typically between 10am and 2pm at mid-latitudes. Circadian signalling from morning light and vitamin D synthesis from midday UV are therefore separate events requiring different protocols. Pursuing vitamin D via early morning light is ineffective at higher latitudes; the circadian benefit is best captured then regardless, because it requires the entire visible spectrum rather than UV.

The interplay between morning sunlight, cortisol, and temperature deserves attention. The cortisol awakening response (CAR) — a 50–100% rise in serum cortisol in the first 30–45 minutes post-waking — is amplified by bright light exposure immediately after waking. A 2014 study by Leproult et al. showed that morning bright light (>2500 lux) within 30 minutes of waking increased CAR magnitude by ~50% versus dim light conditions, with associated improvements in alertness and psychomotor performance. Exercise at the same time amplifies this further via catecholamine release. Cold air temperature (outdoor morning walks versus heated indoor environments) adds a separate thermogenic stimulus. These convergent inputs — light, cortisol, temperature, and physical activity — represent a systems-level morning protocol with mechanistic support for circadian robustness, metabolic activation, and mood stability throughout the day, even without any therapeutic device.

Dosimetry is the most underappreciated aspect of photobiomodulation and the main reason consumer devices vary enormously in efficacy. The key parameters are: irradiance (power density, mW/cm²) at the treatment distance; wavelength(s); total dose (energy density, J/cm² = mW/cm² × seconds ÷ 1000); treatment area (cm²); and treatment frequency. Clinical trials that established efficacy typically delivered 4–60 J/cm² per treatment site. An irradiance of 50 mW/cm² at 15 cm distance for 10 minutes delivers 30 J/cm² — solidly within the therapeutic window for most soft-tissue applications. The same panel at 30 cm delivers approximately 12–15 mW/cm² (inverse square law), requiring 33–40 minutes for the same dose. Published device irradiance figures measured at 6 inches (≈15 cm) from a high-quality panel typically range from 30–120 mW/cm² for reputable full-body panels; values below 10 mW/cm² at any distance suggest insufficient power for clinical dosing without very long sessions.

Wavelength selection matters because different applications optimise in different ranges. For skin and hair (5–10 mm depth), 630–680 nm is appropriate, with 660 nm being the most studied. For muscle, joint, and pain applications (15–30 mm), 810–850 nm or combination 660/850 nm panels are preferred. Consumer "full-body" panels combining 660 nm and 850 nm LEDs in equal or 2:1 ratios are a reasonable compromise for general use. Continuous-wave delivery is most studied; pulsed delivery (10–40 Hz) shows advantages in some brain and retinal studies but no clear superiority for most soft-tissue applications. LED devices are adequate for home use and surface applications; laser devices (coherent light) achieve equivalent biological outcomes at matched doses but are not meaningfully superior for most non-ablative applications per the 2019 meta-analysis by Hochman et al.

Practical quality markers for consumer devices include: independently measured (third-party) irradiance at stated distance; absence of flicker above 3,000 Hz (measurable with a photodiode or smartphone slow-motion camera); minimal heat generation at the stated LED chip; wavelength peak verified by spectrophotometry (many cheap panels claim 660 nm but peak at 620–640 nm or use broad-emission red LEDs with poor spectral purity); and sufficient LED density to achieve uniform field across the treatment area. Reputable manufacturers publish spectral data; most consumer brands do not. For bright-light therapy boxes (SAD treatment), clinical certification requires ≥10,000 lux at 30 cm with UV filter (UV output <1 μW/cm² at 300–400 nm), and the device should have IEC 62471 photobiological safety certification. Home users building a light therapy practice benefit most from starting with a single evidence-based application (SAD box for morning mood, or 660/850 nm panel for targeted tissue application) rather than chasing the broadest-spectrum device, because optimising dosimetry for one goal is more likely to produce measurable results than sub-threshold exposure across many wavelengths.